P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY

• J. Doorduijn,
• S. Issa,
• B. van der Holt,
• M. Minnema,
• T. Seute,
• M. Durian,
• G. Cull,
• M. van der Poel,
• W. Stevens,
• J. Zijlstra,
• M. Nijland,
• K. Mason,
• A. Beeker,
• D. Brandsma,
• M. van den Bent,
• M. Gonzalez,
• D. de Jong,
• J. Bromberg

Affiliations

J. Doorduijn

1 Hematology, Erasmus MC Cancer Institute Rotterdam, Rotterdam, Netherlands

S. Issa

2 Hematology, Middlemore Hospital, Auckland, New Zealand

B. van der Holt

3 HOVON Data Center, Erasmus MC, Rotterdam

M. Minnema

4 Hematology

T. Seute

5 neurology, University Medical Center Utrecht, Utrecht

M. Durian

6 Hematology, ETZ Hospital, Tilburg, Netherlands

G. Cull

7 Hematology, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine, Nedlands, Australia

M. van der Poel

8 Hematology, University Medical Center, Maastricht

W. Stevens

9 Hematology, Radboud University Medical Center, Nijmegen

J. Zijlstra

10 Hematology, Amsterdam UMC, Amsterdam

M. Nijland

11 Hematology, University Medical Center Groningen, Groningen, Netherlands

K. Mason

12 Hematology, Royal Melbourne Hospital, Melbourne, Australia

A. Beeker

13 Hematology, Spaarne Gasthuis, Haarlem

D. Brandsma

14 neurology, Netherlands Cancer Institute, Amsterdam

M. van den Bent

15 neurology, Erasmus MC Cancer Institute Rotterdam, Rotterdam, Netherlands

M. Gonzalez

16 pathology, Royal Melbourne Hospital, Melbourne, Australia

D. de Jong

17 pathology, Amsterdam UMC, Amsterdam, Netherlands

J. Bromberg

15 neurology, Erasmus MC Cancer Institute Rotterdam, Rotterdam, Netherlands